Abstract
Over the last years, short treatment courses for different infections, including respiratory tract infections, are increasingly more discussed. This therapeutic approach has some clear benefits: improved compliance, less frequent adverse drug reactions, decreased risk of selection and distribution of drug-resistant pathogens, and cost-effectiveness. The main question in discussing short courses of antimicrobial therapy is the following: Is shortened duration of treatment (compared to conventional) associated with decreased treatment efficacy? This paper is intended to find answer to the question with regard to the management of patients with community-acquired pneumonia.
-
1.
Bartlett J.G., Breiman R.F., Mandell L.A., et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26:811-38.
-
2.
Sobel J.D., Kaye D. Urinary tract infections. In: Principles and Practice of Infectious Diseases, vol. 1, 4th edn (Mandell GI, Bennett JE, Dolin R, eds). New York: Churchill Livingstone, 1995; p. 662-90.
-
3.
Boerema J.B., Willems F.T. Fosfomycin trometanol in single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infection in general practice. Infection 1990; 18 (Suppl 2):S80-S88.
-
4.
Haizlip J., Isbey S.F., Hamilton H.A., et al. Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. Sex Transm Dis 1995; 22:145-8.
-
5.
De Montalembert M. Bacterial meningitis in children: how many lumbar punctures? Pediatrie 1993; 48:17-9.
-
6.
Carlin S.A., Marchant C.D., Shurin P.A., et al. Host factors and early therapeutic response in acute otitis media. J Pediatr 1991; 118; 178-83.
-
7.
Pechère J-C. Modelling and predicting clinical outcomes of antibiotic therapy. Infect Med 1998; 15 (Suppl E): 46-54.
-
8.
Taylor Z., Nolan C.M., Blumberg H.M., ATS, CDC and IDSA. Controlling tuberculosis in the United States. MMWR Recomm Rep 2005; 54 (RR-12):1-81.
-
9.
Yousefi-Nooraie R., Mortaz-Hejri S., Mehrani M., Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012; 10:CD007179.
-
10.
Wilson W.R., Karchmer A.W., Dajani A.J., et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms. JAMA 1995; 274:1706-13.
-
11.
Mandell L.A., Wunderink R.G., Antonio A., et al. Infectious Diseases Society of America / American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007;44 (Suppl 2):S27-S72.
-
12.
Lim W.S., Baudouin S.V., George R.C., et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64(Suppl III):iii1–iii55.
-
13.
Woodhead M., Blasi F., Ewig S. and the ERS/ESCMID Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011; 17 (Suppl. 6):1-59.
-
14.
Чучалин А.Г., Синопальников А.И., Козлов Р.С. и соавт. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике (Пособие для врачей). Клин микробиол антимироб химиотер 2010; 12(3):183-268.
-
15.
Mandell L.A., Bartlett J.G., Dowell S.F., et al. Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults. Clin Inf Dis 2003; 37:1405-33.
-
16.
Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
-
17.
Metlay J.P., Atlas S.J., Borowsky L.H., Singer D.E. Time course of symptom resolution in patients with communityacquired pneumonia. Respir Med 1998; 92:1137-42.
-
18.
Christ-Crain M., Stoltz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93.
-
19.
Schuetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory rtact infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059-66.
-
20.
Christ-Crain M., Jaccard-Stoltz D., Bingisser R., et al. Effect of procalcitonin0guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-7.
-
21.
Long W., Deng X., Zhang Y., et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011; 16:819-24.
-
22.
Kristffersen K.B., Søgaard O.S., Wejse C., et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission – a randomized trial. Clin Microbiol Infect 2009; 15:481-7.
-
23.
Esposito S., Esposito I., Leone S. Considerations of antibiotic therapy duration in community- and hospitalacquired bacterial infections. J Antimicrob Chemother 2012; 67:2570-5.
-
24.
Guillemont D., Carbon C., Balkau B., et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279:365-70.
-
25.
File T.M.Jr. Clinical efficacy of newer agents in shortduration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39:159-64.
-
26.
Scalera N.M., File T.M.Jr. How long should we treat community-acquired pneumonia? Curr Opin Infect Dis 2007; 20:177-81.
-
27.
Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a clinical review. Int J Antimicrob Agents 2002; 19:261-8.
-
28.
Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
-
29.
Cecil R.L., McDermott W., editors. Textbook of medicine. 7th ed. Philadelphia: WB Saunders Co.; 1948.
-
30.
Harrison T.R., Resnick W.R., Wintrobe M.M., et al., editors. Principles of internal medicine. 5th ed. New York: McGraw Hill; 1967.
-
31.
Witt R.L., Hamburger M. The nature and treatment of pneumococcal pneumonia. Med Clin North Am 1963; 47:1257-70.
-
32.
Halm E.A., Fine M.J., Marrie T.J., et al. Time to clinical stability in patients hospitalized with communityacquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452-7.
-
33.
Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol 1979; 73:235-40.
-
34.
El Moussaoui R., de Borgie CAJM, van den Broek. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomized, double blind study. BMJ 2006; 332:1355.
-
35.
Pichicero M. Short courses of antibiotic in acute otitis media and sinusitis infections. J Int Med Res 2000; 28 (Suppl):25A-36A.
-
36.
Guay D.R. Short course antimicrobial therapy for upper respiratory tract infections. Clin Ther 2000; 22:673-84.
-
37.
MASCOT group. Clinical efficacy of three days versus five days of oral amoxicillin for the treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360:835-41.
-
38.
ISCAP study group. Three days versus five days treatment with amoxicillin for nonsevere pneumonia in young children: a multicentre randomized controlled trial. BMJ 2004; 328:791-4.
-
39.
Schrag S.J., Pena C., Fernandez J., et al. Effect of short-course, high dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2000; 286:49-56.
-
40.
File T.M.Jr. A new dosing paradigm: high-dose, shortcourse fluoroquinolone therapy for community-acquired pneumonia. Clinical Cornerstone 2003; Suppl 3:S21-S28.
-
41.
Zelenitsky S.A., Ariano R.E., Iacovides H., et al. AUC0-t/ MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 2003; 51:905-11.
-
42.
Dunbar L.M., Wunderink R.G., Habib M.P., et al. Highdose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60.
-
43.
Shorr A.F., Zadeikis N., Xiang J.X., et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia. Clin Ther 2005; 27:1251-9.
-
44.
File Jr.T.M., Mandell L.A., Tillotson G., et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double blind study. J Antimicrob Chemother 2007; 60:112-20.
-
45.
D’Ignazio J., Camere M.A., Lewis D.E., et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for reatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49:4035-41.
-
46.
Baldwin D.R., Wise R., Andrews J.M., et al. Azithromycinconcentrations at the sites of pulmonary infection. Eur Resp J 1990; 3:886-90.
-
47.
Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and 3-day course. J Chemother 1998; 10:64-8.
-
48.
O’Doherty B., Muller O., and azithromycin study group. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate communityacquired pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17:828-33.
-
49.
Sopena N., Martinez-Vazquez C., Rodrigues-Suarez J.R., et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J Chemother 2004; 16:102-3.
-
50.
Drehobl M.A., De Salvo M.C., Lewi D.E., Breen J.D. Single-dose azithromycin microspheres vs. clarithromycin extended release for the treatment of mild to moderate community-acquired pneumonia in adults. Chest 2005; 128:2230-7.
-
51.
Leophonte P., Choutet P., Gaillat J., et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect 2002; 32:369-81.
-
52.
Dunbar L.M., Khashab M.M., Kahn J.B., et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20:555-63.
-
53.
Tellier G., Chang J.R., Asche C.V., et al. Comparison of hospitalization rates in patients with communityacquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr Med Res Opin 2004; 20:739-47.
-
54.
Li J.Z., Winston L., Moore H., Bent S. Effectiveness of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis of randomized controlled trials. In: Abstracts of the 46th ICAAC meeting; 17-20 September 2006, San Francisco. Washington, DC: ICAAC; 2006. Abstract L-1458.
-
55.
Li J.Z., Winston L., Moore H., Bent S. Effectiveness of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120:783-90.
-
56.
Dimopoulos G., Matthaiou D.K., Karageorgopoulos D.E., et al. Short-versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008; 68:1841-54.
-
57.
Nair G.B., Niederman M.S. Community-acquired pneumonia: an unfinished battle. Med Clin N Amer 2011; 95:1143-61.
-
58.
Montassier E., Goffinet N., Potel G., Batard E. How to reduce antibiotic consumption for community-acquired pneumonia? Med Malad Infect 2013; 43:52-9.